Friday 6 November 2026
Export NAGE’s income statement to Excel — free account
Niagen Bioscience, Inc.
NAGE Consumer Defensive Packaged Foods
Niagen Bioscience, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $129.4 million, up 29.9% from fiscal 2024.
- Revenue
- −20.0%
- EPS
- −124.7%
- Free cash flow
- −28.4%
Quarter to September 2026, against a year earlier
2.07
0.04
−1.90%
Follow NAGE
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
| 13.32% | 21.80% | 27.07% | 28.35% |
+8 more TTM periods Free account |
|
Piotroski F-Score |
4 | 5 | 5 | 6 | |
| 9.90% | 16.14% | 19.05% | 19.90% | ||
ROIC |
22.00% | 41.95% | 51.81% | 86.63% | |
Return on Tangible Assets |
12.11% | 19.04% | 22.29% | 22.22% | |
Average Days of Receivables |
20.42 | 24.26 | 36.57 | 27.47 | |
Free Cash Flow per Share |
0.12 | 0.14 | 0.12 | 0.17 | |
Free Cash Flow |
9.88 | 11.47 | 9.91 | 13.21 | |
Capital Expenditures |
5.00 | 5.53 | 5.48 | (0.29) | |
| Other line items | |||||
Cash ROIC |
6.48% | 7.69% | 6.65% | 9.35% | |
Accounts Receivable Turnover |
15.94 | 14.16 | 12.96 | 14.78 | |
Accounts Payable Turnover |
3.65 | 3.99 | 3.90 | 4.79 | |
Inventory Turnover |
2.25 | 2.63 | 2.65 | 3.12 | |
Average Days of Payables |
95.01 | 74.63 | 104.03 | 85.23 | |
Days of Inventory on Hand |
169.52 | 163.20 | 188.18 | 161.24 | |
Tax Rate |
0.00 | (0.06) | (0.05) | (0.04) | |
Research and Development Expense of Revenue |
5.32% | 5.03% | 5.02% | 4.89% | |
Selling, General and Administrative Expense of Revenue |
56.27% | 52.53% | 50.75% | 48.34% | |
Share Based Compensation of Revenue |
5.49% | 5.38% | 5.14% | 4.69% | |
Operating CF/Net income |
0.48 | 0.37 | 0.24 | 0.78 | |
Depreciation/Fixed assets |
0.88 | 0.78 | 0.68 | 0.59 | |
Capex/Depreciation |
4.67 | 5.66 | 6.22 | (0.37) | |
Revenue per Share |
1.55 | 1.63 | 1.63 | 1.63 | |
Operating CF per Share |
0.06 | 0.08 | 0.06 | 0.17 | |
Capex per Share |
0.06 | 0.07 | 0.07 | 0.00 | |
Capex to Sales |
(0.04) | (0.04) | (0.04) | 0.00 |
Columns are period end dates · fundamentals updated 6 Nov 2026